No Data
No Data
Sunshine Biopharma Announces Canadian Subsidiary Nora Pharma Acquired Two Gastrointestinal Drugs; Launches Prucalopride For Chronic Constipation, Second Drug Launch Planned in 9 Months. Gastrointestinal Market Worth In Excess Of C$200M Per Year.
Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market
Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT
Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer
Sunshine Biopharma Files For Offering Of Mixed Shelf Of Up To $100M
Express News | Sunshine Biopharma Announces Development Of An Orally Active Protease Inhibitor With Dose-Dependent Antiviral Activity In Mice With SARS-CoV-2)